General
Preferred name
ragaglitazar
Synonyms
(-)-DRF 2725 ()
NNC 61-0029 ()
(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID ()
Nnc-61-0029 ()
Nnc 61-0029 ()
(-)-drf 2725 ()
P&D ID
PD005563
CAS
222834-30-2
Tags
available
drug candidate
Drug indication
Type-1 diabetes
Drug Status
investigational
experimental
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
1515
DESCRIPTION
Ragaglitazar(NNC-61-0029) is a potent dual activator of PPAR?? and PPAR??, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
5
ChEMBL Drugs
DrugBank
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
18
Molecular Weight
419.17
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
3
cLogP
5.04
TPSA
68.23
Fraction CSP3
0.24
Chiral centers
1.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PPAR
Pathway
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Source data
